Compare · GNPX vs LLY
GNPX vs LLY
Side-by-side comparison of Genprex Inc. (GNPX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNPX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $234.46B, about 2679.9x GNPX ($87.5M).
- LLY has been more active in the news (10 items in the past 4 weeks vs 6 for GNPX).
- LLY has more recent analyst coverage (25 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- Eli Lilly and Company
- Price
- $1.00-2.91%
- $884.02-3.63%
- Market cap
- $87.5M
- $234.46B
- 1M return
- -48.85%
- -
- 1Y return
- -93.06%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 6
- 10
- Recent ratings
- 0
- 25
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest GNPX
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
- Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
- SEC Form PRE 14A filed by Genprex Inc.
- SEC Form 4 filed by Longnecker Brent M
- SEC Form 10-K filed by Genprex Inc.
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
- Genprex to Participate at BIO Europe Spring 2026
Latest LLY
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
- Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.